| FDA | Food and Drug Administration |
| MMR | mismatch repair |
| IHC | immunohistochemistry |
| MLH1 | mutL homologue 1 |
| MSH2 | mutS homologue 2 |
| MSH6 | mutS homologue 6 |
| PMS2 | postmeiotic segregation increased 2 |
| MSI | Microsatellite instability |
| hMMR | MMR-heterogeneous |
| dMMR | MMR-deficient |
| pMMR | MMR-proficient |
| PTEN | Phosphatase and tensin homolog |
| PI3K | phosphatidylinositol-3-kinase |
| Akt | protein kinase B |
| BCIRG | Breast Cancer International Research Group |
| ER | estrogen receptor |
| SCNA | somatic copy number alteration |
| HR | hazard ratio |
| PPV | positive predictive value |
| PR | progesterone receptor |
| LDT | locally developed tests |
| TNBCs | triple-negative breast cancers |
| TMAs | tissue microarrays |
| PD-L1 | programmed death-ligand 1 |
| IRB | Institutional Review Board |
| SD | standard deviation |
| WHO | World Health Organization |
| AJCC | American Joint Committee on Cancer |
| FFPE | formalin-fixed, paraffin-embedded |
| CAP | College of American Pathologists |
| OR | odds ratio |
| CI | confidence interval |